Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
|
|
- Duane Lawrence
- 5 years ago
- Views:
Transcription
1 Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
2 No Disclosures
3 Objectives Recognize early signs of RA/PsA what to ask, what to look for, what to order, when to refer Review treatment for RA/PsA and how it impacts the patient s general health Review importance of managing co morbidities in patients with RA/PsA
4 Rheumatoid arthritis Most common chronic inflammatory arthritis Primary site of pathology is joint synovium pannus Etiology unknown Genetics Environmental factors (smoking, silica) 1% adults in USA Age All races (Native American have higher prevalence) Female > males 2-3:1
5 Psoriatic arthritis Inflammatory arthritis affecting 7-42% patients with psoriasis Psoriasis prevalence 2-3% population White 2x > other races No relation between extent of psoriasis and severity of arthritis In most patients, psoriasis precedes arthritis 6-10 years (can be vice versa in 1/3 of patients)
6 Recognize early signs of RA/PsA what to ask, what to look for RA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules PsA More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) Skin and nail exam findings Tendonitis, enthesitis Dactylitis
7 Recognize early signs of RA/PsA what to ask, what to look for RA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules
8 Recognize early signs of RA/PsA what to ask, what to look for RA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules
9 Recognize early signs of RA/PsA what to ask, what to look for RA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules
10
11 Recognize early signs of RA/PsA what to ask, what to look for PsA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) inflammatory back pain Skin and nail exam findings Tendonitis, enthesitis Dactylitis
12 Recognize early signs of RA/PsA what to ask, what to look for PsA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) Skin and nail exam findings Tendonitis, enthesitis Dactylitis = sausage digits
13 Recognize early signs of RA/PsA what to ask, what to look for PsA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) Skin and nail exam findings Tendonitis, enthesitis Dactylitis
14 Recognize early signs of RA/PsA what to ask, what to look for PsA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) Skin and nail exam findings Tendonitis, enthesitis Dactylitis
15 Recognize early signs of RA/PsA what to ask, what to look for PsA Synovitis (swelling, effusion, warmth, pain) Symmetric joint involvement (small joints MCPs, PIPs, wrists, elbows, ankles, MTPs) > 6 weeks duration Morning stiffness > 1 hour Subcutaneous nodules More commonly asymmetric Oligoarticular Small and large joints Axial involvement (spine, SI joints) Skin and nail exam findings Tendonitis, enthesitis Dactylitis
16 Osteoarthritis, not RA
17 Recognize early signs of RA/PsA what to ask, what to look for extraarticular manifestations RA Constitutional symptoms Episcleritis, scleritis Pericarditis, pleuritis Interstitial lung disease Osteoporosis Atheroslerosis Vasculitis Felty s syndrome Sjogren s Amyloidosis PsA Iritis/Uveitis conjunctivitis Nonspecific colitis Nails Pitts, transverse ridges, onycholysis, hyperkeratosis Urethritis Oral ulcers Aortic insufficiency (rare)
18 6 or more points = RA Ann Rheum Dis 69:
19 Recognize early signs of RA/PsA what to order, clues to diagnosis RA/PsA CBC, CMP ESR and CRP RF and CCP antibody (RA only). ANA panel positive in 30% patients Hepatitis panel Quantiferon TB gold Inflammatory fluid (WBC > 5k 50k) Xrays (look for periarticular osteopenia, erosions, pencil-in-cup deformity ) HIV for severe psoriasis CXR, especially in smokers (higher incidence of ILD in RA patients)
20 RA PsA
21 Just because RF is +, doesn t mean it s RA Differential: HEPATITIS B and C (HCV can mimic RA symptoms) Cryoglobulins Sjogren s Syndrome (with or without SSA and SSB, + sicca symptoms) SLE Sarcoidosis Subacute bacterial endocarditis
22 Just because RF is (-) doesn t mean it s NOT RA 10% are seronegative CCP + in 10-15% of RF negative RA patients
23 Recognize early signs of RA/PsA when to refer Suspicion high Positive serologies Erosions on xrays Targeted treatment within first 3-6 mo of symptom onset associated with better outcomes
24 Review treatment for RA/PsA and how it impacts the patient s general health Synthetic DMARDS Anti-TNF Anti-IL-6 Anti CD 80/86 Jak kinase inhibitor Anti- CD20 Il-17 PDE inhibitor Anti IL-12/IL-23 Methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, cyclosporine Enbrel, Humira, Simponi, Remicade, Inflectra, Cimzia Actemra, Kevzara Orencia Xeljanz (oral) Rituximab Cosentyx, Taltz Otezla Stelara
25 Which one do we use or start with? Depends on severity of disease and comorbidities? Infection risk? Liver disease? Pregnancy? Hx of TB exposure? CHF Initially start conventional synthetic DMARD (mono therapy or in combination) Biologic if DMARDs ineffective or intolerance Insurance coverage may impact decision on which specific one
26 General facts and FAQs Main risk for most DMARDs and for ALL biologics are INFECTIONs This includes steroids! Consider them immunosuppressed/immunocompromised Strict Lab monitoring every 1-3 mo: Methotrexate, leflunomide, xeljanz, sulfasalazine, Actemra, Kevzara CBC and CMP Lipid panel for xeljanz, Actemra No live vaccine (ie shingles) while on biologic Give live vaccine 4 weeks before starting biologic Wait 3 mo after stopping to give it if already on biologic (ok to give if prednisone dose < 20 mg a day, MTX < 0.4 mg/kg/week) Before treatment: screen for hepatitis B and C and TB TB screen once yearly for biologic
27 General facts and FAQs Special consideration: Glucocorticoids Start lowest dose possible, d/c as soon as disease activity permits Implement fall prevention program Avoid immobilization, encourage weight bearing exercises Calcium and vit D Bisphosphonates, esp for high risk patients Think AVN for acute and severe hip or knee pain Glucose intolerance Osteonecrosis Cataracts Skin changes Delayed wound repair Peptic ulcer (w/nsaids) Weight gain Infection HTN Abnormal menstruation Mental disturbance Weakness Osteoporosis
28 General facts and FAQs Special consideration: MTX and leflunomide watch closely for liver disease, minimize etoh use (best to avoid), needs close lab monitoring CBC/CMP (monthly at start, then q 3 mo maintenance) MTX rare reaction causing pneumonitis Anti-TNF therapy drug induced lupus, demyelinating disease, CHF exacerbation NSAIDs Not disease modifying Cautious use in elderly Cardio, nephro and GI toxicities
29 General facts and FAQs Preoperative management: No need to stop plaquenil, sulfasalazine MTX or arava (can hold the week of surgery) Biologic hold 1 dose of the biologic prior, can resume 2-4 weeks after RA patients xray C spine (dynamic view flex/ext to assess for C1-C2 subluxation)
30 Review importance of managing co morbidities in patients with RA/PsA Increased mortality in RA patients: Cardiovascular frequency increased 2x over general population Infection (esp pneumonias) 5x over general population Cancer Leukemia and lymphoma 2-3x over general population Lung cancer x over general population Increased mortality in Psoriatic patients Metabolic syndrome Hyperuricemia Obesity Premature atherosclerosis
31 Review importance of managing co morbidities in patients with RA/PsA Increased morbidity: GI hemorrhage (NSAIDs) Fractures from osteoporosis (RA and steroids) Lung disease ILD, BOOP Medication toxicity Sjogren s Obesity Depression Fatigue Chronic pain
32 Preventative therapy Immunizations Flu, pneumovax NO live vaccines for patients on biologics Cardiovascular risk factor modification Smoking BP monitoring Lipids Screen for depression Situational Medication related (ie-steroids) Fatigue very common Osteoporosis Calcium and Vit D Anti-resorptive therapy
33 Pregnancy and lactation 50-75% of patients with RA improve during pregnancy Always discuss birth control and pregnancy planning at every visit for patients of child bearing age Safe meds: Sulafasalazine Hydroxychloroquine Low dose prednisone (5-10 mg/day) Anti-TNF therapy (Cimzia the safest) Stelara Contraindicated meds: Methotrexate Leflunomide Limited data in other biologics Stop meds 3 months before conception
34 References and patient resources Sterling West. Rheumatology Secrets. Third edition
Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationMary Derlacki, FNP. No financial relationships to disclose. Office Rheumatology for the Nurse Practitioner. Rheumatoid Arthritis
Office Rheumatology for the Nurse Practitioner Mary Derlacki, FNP Drs. Cassell and Boren Eugene, OR 541-687-0816 mderlacki@comcast.net No financial relationships to disclose Rheumatoid Arthritis 1% of
More informationEARLY INFLAMMATORY ARTHRITIS. Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital
EARLY INFLAMMATORY ARTHRITIS Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital EIA: Introduction National priority Preventable cause of disability Very common condition High
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationBSR Biologics Register Rheumatoid Arthritis Clinical Baseline Form
BSR Biologics Register Rheumatoid Arthritis Clinical Baseline Form Please complete the following PATIENT information ID For office use only Gender: Male Female Date of birth: D D M M Y Y Y Y Hospital Reg.
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationBasic Approach/Goals. Medical Management of Rheumatic Diseases. Acetaminophen. Anti-inflammatories (NSAIDs) Steroids.
Basic Approach/Goals Medical Management of Rheumatic Diseases Diane Lacaille, Rheumatologist ACE Workshop April 23, 2018 1) Symptom control: Acetaminophen, NSAIDs, steroids (intraart, po) 2) Prevention
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationRheumatology Primer: What Labs and When
Rheumatology Primer: What Labs and When Irina Konon, MD Department of Internal Medicine Division of Rheumatology Medical College of Wisconsin Disclosures None 1 Objective Discuss principles of laboratory
More informationThe Role of the Physician Assistant in the Management of the RA Patient
For your information Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Private practice, Tustin CA Investigator in clinical trials relevant to this lecture including: anti-tnf for
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationwww.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationWhen is it Rheumatoid Arthritis When to Refer
When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationPharmacy Management Drug Policy
SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationRheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy
Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationEffective management of arthritis. Gail Dolan Victoria ACH Liz McIvor Stobhill ACH
Effective management of arthritis Gail Dolan Victoria ACH Liz McIvor Stobhill ACH Role Types of arthritis Drugs Self Management Role Of CNS Advanced level nurses offering specialist care in a specific
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationUndifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
More informationJuvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationClinical Practice Guideline. Rheumatoid Arthritis (RA) Adult. Version
Clinical Practice Guideline Rheumatoid Arthritis (RA) Adult Version 1.1.2017 June 2017 Table of Contents Introduction... 5 Diagnosis... 8 Determining the Diagnosis... 8 Laboratory Tests...10 Patient Assessment...11
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Oxford Clinical Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHARMACY 292.4 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationRheum-inations For the physical therapist
Rheum-inations For the physical therapist All you wanted to know about rheumatology and more! Susan Shenoi MD, MS, RhMsUS Assistant Professor Clinical Director Seattle Children s Hospital 10-2017 Objectives
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationRheumatology Updates for Primary Care Olympic Peninsula Medical Conference. Erin M. Bauer MD Rheumatology
Rheumatology Updates for Primary Care Olympic Peninsula Medical Conference Erin M. Bauer MD Rheumatology November 2017 Objectives 1. Discuss common Rheumatology referrals and diagnoses 2. Describe initial
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationJIA and Other Rheumatic Diseases in Children. Norma Liburd, RN-BC, MN
JIA and Other Rheumatic Diseases in Children Norma Liburd, RN-BC, MN Define Juvenile Idiopathic Arthritis (JIA) and discuss the diagnostic criteria. Objectives Identify the subtypes of JIA and discuss
More informationDisclosures. Goals. Rheumatology Review for Primary Care. No commercial disclosures. We will be discussing non-fda approved uses for some medications.
Rheumatology Review for Primary Care April 27, 2018 MONA Coming Together in Advanced Practice Disclosures No commercial disclosures. We will be discussing non-fda approved uses for some medications. Goals
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationRheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Rheumatic Diseases The prevalence of rheumatoid arthritis in most Caucasian populations approaches 1% among adults 18 and over and
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationRheumatology for GP Trainees: Inflammatory Arthritides (RA Including Early Recognition and Pharmacotherapeutics)
Rheumatology for GP Trainees: Inflammatory Arthritides (RA Including Early Recognition and Pharmacotherapeutics) Dr Martin Lee MRCP(Rheum) Rheumatology Consultant and Associate Clinical Lecturer The Freeman
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 284.9 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationThe Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics
+ The Rheumatoid Hand Deformities & Management Dr. Anirudh Sharma Resident Department of Orthopedics + Why is Rheumatoid Arthritis important? + RA is a very debilitating disease median life expectancy
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationNew Onset Arthritis. Clinical Dilemmas in Arthritis and Rheumatology. Physical Examination. Other Pertinent History
New Onset Arthritis Clinical Dilemmas in Arthritis and Rheumatology Primary Care Principles and Practice October 2008 Jonathan Graf, MD Assistant Professor of Medicine, UCSF Division of Rheumatology, SFGH
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0043I Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationHigh Impact Rheumatology
High Impact Rheumatology Evaluation and Management of Rheumatoid Arthritis Rheumatoid Arthritis: Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationBirthdate: / / Address: Age: Sex: M F. Telephone: H ( ) City State Zip W ( ) C ( )
Please complete this questionnaire in its entirety, even if you feel some questions may not apply to you. Our staff is available should you have any questions, or need assistance with the completion of
More informationClinical Challenges in Arthritis: Care Plans and Interventions That Achieve Results Primary Care Updates Boston, Massachusetts September 19, 2013
Clinical Challenges in Arthritis: Care Plans and Interventions That Achieve Results Primary Care Updates Boston, Massachusetts September 19, 2013 Content Collaborator: Session 1: Clinical Challenges in
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationSubject: Remicade (Page 1 of 5)
Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 10 Last Review Date: June 22, 2018 Enbrel Description Enbrel (etanercept),
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationRheumatologic Manifestations of Gastrointestinal Diseases
Rheumatologic Manifestations of Gastrointestinal Diseases NATASHA DEHGHAN, MD, FRCPC CLINICAL ASSISTANT PROFESSOR VASCULITIS CLINIC, MARY PACK ARTHRITIS CENTRE Objectives To discuss a few common rheumatologic
More informationJeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400
Jeopardy Antibodies & more antibodies Aching joints What s the rash? Potpourri Image Challenge $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information2018 ReachMD Page 1 of 10
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationHow do polyarthritis, polyarthralgias, and diffuse aches and pains differ?
Approach to the patient with polyarthritis How do polyarthritis, polyarthralgias, and diffuse aches and pains differ? Polyarthritis is definite inflammation (swelling, tenderness, warmth) of more than
More informationClinical Practice Guideline. Rheumatoid Arthritis (RA) Adult. Version
Clinical Practice Guideline Rheumatoid Arthritis (RA) Adult Version 1.1.2018 August 2018 Table of Contents Introduction... 5 Diagnosis... 8 Determining the Diagnosis... 8 Laboratory Tests... 11 Patient
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More information